Teleflex presents clinical data showing UroLift system benefits
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Teleflex Showcases New Clinical Data at Leading Urological Congresses Highlighting Patient Experience Advantages of the UroLift™ System and Long-Term Toxicity Reduction with Barrigel™ Rectal Space
May 21, 2026 6:30 AM EDTFirst Head-to-Head Randomized Control Study (RCT) Reinforces Early Patient Experience Benefits and 12-month Durability of the UroLift System versus Rezm1
Three-Year Data Demonstrate Sustained Reduction in Gastrointestinal Toxicity with Barrigel Rectal Spacer2
WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the Interventional Urology Business Unit has released new clinical data across two major urological congresses, reinforcing the value of the UroLift System and Barrigel rectal spacer in improving patient-centered outcomes across benign prostatic hyperplasia (BPH) and prostate cancer... More
